Transforming lives with antibody science
Genmab (genmab.com) earns a Brand Analyzer score of 83 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 4769 Healthcare brands analyzed, Genmab ranks in the 84th percentile (category average 74, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 100/100, Visual Identity 93/100, Messaging Clarity 95/100, Trust Foundation 90/100, AI Discoverability 46/100, Brand Authority 58/100.
Genmab is a Danish biotechnology company founded in 1998 and headquartered in Copenhagen. It specializes in the research and development of antibody therapeutics for cancer and other serious diseases. Using pioneering antibody science and proprietary technology platforms, Genmab develops differentiated treatments aimed at addressing unmet medical needs. The company serves patients, healthcare providers, biopharmaceutical partners, and the broader medical and scientific community, positioning itself as a global leader in innovative antibody therapeutics.
| Brand Name | Genmab |
|---|---|
| Domain | genmab.com |
| Industry | Healthcare |
| Founded | 1998 |
| Headquarters | Copenhagen |
| Main Competitors | Regeneron Pharmaceuticals (92/100), Amgen (82/100), Roche/Genentech (83/100), AbbVie (84/100), Seagen, MorphoSys, Innate Pharma, Daiichi Sankyo (79/100) |
Moz Domain Authority 52/100 vs category average 38 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #324,403 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Genmab has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Genmab is an international biotech company specializing in antibody therapeutics for the treatment of cancer and other serious diseases" (Meta description: 19 words (ideal length). No OG description (falling back to meta)) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:image, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, GitHub; no detected presence on Facebook, YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Genmab scores 52/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Genmab has a limited AI-visibility profile at 52/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (22/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #324,403 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Genmab from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Genmab?", Claude could identify the brand as of August 2026. Genmab is a Danish biotechnology company specializing in the creation of differentiated antibody therapeutics for cancer treatment, using its proprietary antibody technology platforms. It has co-developed several blockbuster oncology drugs, most notably Darzalex (daratumumab) wit Best known for Co-developing the multiple myeloma drug Darzalex (daratumumab).
When asked "Best brands similar to Genmab?", Claude would recommend Genmab as of August 2026. It's a leading name in antibody-based cancer therapeutics with a strong track record of successful partnered drugs, making it a natural mention alongside other top oncology biotech firms.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Genmab's main competitors include Regeneron Pharmaceuticals (92/100), Amgen (82/100), Roche/Genentech (83/100), AbbVie (84/100), Seagen. These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Genmab and Regeneron Pharmaceuticals are competitors in Healthcare. Brand Analyzer scores Genmab at 83/100 and Regeneron Pharmaceuticals at 92/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Genmab include Regeneron Pharmaceuticals (92/100), Amgen (82/100), Roche/Genentech (83/100), AbbVie (84/100), Seagen. Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, founded in 1998. It specializes in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases.
Sources: Genmab official site
Genmab has moderate AI-search visibility, scoring 52/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 22, recommendation 54). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Genmab official site
Genmab was founded in 1998. Genmab operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Genmab is headquartered in Copenhagen. Genmab operates in the Healthcare category.
Sources: Wikidata
Genmab researches, develops, and creates antibody-based therapeutics aimed at treating cancer and other serious diseases. It uses proprietary antibody science and technology platforms to design differentiated treatments that address unmet medical needs, often in collaboration with biopharmaceutical partners.
Sources: Genmab official site
Genmab scores 54/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Genmab official site
Genmab offers antibody therapeutics designed to treat cancer and other serious diseases. These are developed using the company's proprietary antibody science and technology platforms, targeting unmet medical needs in oncology and related fields.
Sources: Genmab official site
Genmab can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Genmab official site
Genmab's therapeutics and research are used by patients with cancer and other serious diseases, as well as healthcare providers who administer treatments. The company also collaborates with biopharmaceutical partners and engages with the broader medical and scientific community in the development of its antibody therapeutics.
Sources: Genmab official site
Genmab is known for its expertise in antibody therapeutics and its proprietary technology platforms used to create innovative treatments for cancer and other serious diseases. The company is recognized within the biotechnology sector as a specialist in antibody science.
Sources: Genmab official site
Ranked closest to Genmab: Genedata (83/100), Foothold Technology (83/100), The GEO Group (83/100), Gimv (83/100).
A step up - brands to learn from: theSkimm (91/100), Replika (91/100).
Category leader: Elsevier (96/100).